Clinical Trial: Gut Imaging for Function and Transit in Cystic Fibrosis 3 Junior
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Condition: Cystic Fibrosis
Study Type: Observational
Official Title: Gut Imaging for Function and Transit in Cystic Fibrosis 3 Junior: an Evaluation of Triple Combination Therapy in Children Aged 6 to 11 Years
Brief Summary:
Recently trial data has shown that the medicine KaftrioTM (Elexacaftor/ Tezacaftor/ Ivacaftor) improves lung function in children aged 6 to 11 years who have cystic fibrosis (CF). This has led to it being licensed for use in the UK in 2022 and is now being prescribed in this age group. There is little information in trials however that shows the effect KaftrioTM (ETI) has on the gut or liver in this age group.Previous studies in the GIFT-CF series (NCT 03566550, NCT04006873 and NCT04618185) has found differences…
Read more